The Scrambler Therapy® device ST-5A (Made in Italy) replaces the previous model MC-5A
The Scrambler Therapy® Technology ST-5A is a patented non-invasive electro-analgesia device with 5 channels that deliver low-intensity stimuli (max. 5 mA) generated by a completely automated treatment program. Five artificial neurons create “packets” (strings) of information recognized as “non-pain,” the content of which is controlled by a proprietary algorithm. This various information of “no pain” produces an immediate analgesic effect, capable of eliminating pain in real time. Up to 5 pairs of independent electrodes can be placed on the patient's body based on the need of the treatment. Two microprocessors ensure the correct operation of the device by automatically establishing the optimal parameters of effectiveness and safety, which cannot be modified by the operator. The placement of the electrodes requires scrupulous observance of the method of identifying the areas of pain treatment. If the treatment is performed correctly, normally the pain is zeroed (or reduced very close to zero) in real time regardless of the initial intensity and the pathology that generated it.
This therapy was born from the start to treat chronic neuropathic and oncological pain, and in particular forms refractory to other therapies and opioids. For this reason, the substantial totality of the clinical studies published on this therapy before and after the placing on the market specifically concerns this type of pain.
The Scrambler Therapy® device has been used to successfully treat
thousands of patients worldwide, where it has been shown to be
effective in treating neuropathic and oncologic pain. Scrambler
Therapy® Technology ST-5A is a stand-alone medical
electro-analgesia device and does not require combinations with
other analgesic therapies. This medical device has been developed
in Italy by Prof. Giuseppe Marineo.
In Scrambler Therapy®, the therapeutic approach is no longer to inhibit the transmission of pain but to transform the information of pain into “non-pain” using the same pathways. In the Scrambler Therapy® model, information becomes the central point of control of the plasticity of the pain system, both in the genesis of chronicity (induced by endogenous information of pain repeated over time) and in its regression (induced by synthetic information of “no pain” repeated over time). The result of this theoretical model applied in the Scrambler Therapy® medical device is an immediate and complete analgesic effect in treatment and the return to normal physiological response after one or more cycles of treatment. Considering this specific approach, it is quite clear that the concept of similarity that only considers the parameters of frequency, pulse width, and intensity (used in other devices) for this technology is not applicable because they do not generate and do not characterize the specific information of “no pain” of the Scrambler Therapy®. In this sense any modification of the emissions of the Scrambler Therapy in the form and organization of the flows in time (i.e., the specific strings of “no pain” information) is functionally equivalent to the modification of the chemical formula of a drug.
Scrambler Therapy®, if correctly used, is a powerful control tool for severe chronic neuropathic and cancer pain. Scrambler Therapy® is very effective and non-invasive and is mainly to be used in ambulatory care and hospital facilities. If carried out correctly, the analgesic effect during the treatment is very rapid. In just a couple of seconds the pain perception completely disappears. This is true even in cases where pain is of high intensity and nonresponsive or poorly responsive to opioids or other electro-analgesia devices such as TENS or implanted devices. Short- and long-term effects of a single treatment cycle depend on the type of pathology and other variables. In most cases of benign pain, one treatment cycle is enough to produce pain relief for at least two months but can even exceed 12 months if neuropathic damage is limited (mono-radicular) or the pathology has no evolution feature. Other variables that influence the treatment outcome are pharmaceutical interactions. Immediate analgesic efficacy during the treatment is a constant factor regardless of pathology and pain intensity.
For more information visit the Official Scrambler Therapy® scientific and clinical information website .
DIS&L through its law firm is the only company authorized to sign international exclusive agreements in all international areas and provide maintenance and distributor support for method usage training and other logistics needs. To request a national exclusive agreement, the candidate distributor must have minimum requirements listed on the “ Distributor Requirement ” page.
Copyright © DIS&L. All rights reserved
